Discounted Cash Flow (DCF) Analysis Levered

NexImmune, Inc. (NEXI)

$0.65

+0.01 (+2.36%)
All numbers are in Millions, Currency in USD

Free Cash Flow

Year
A/P
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue ---------
Revenue (%)
Operating Cash Flow ---------
Operating Cash Flow (%)
Capital Expenditure ---------
Capital Expenditure (%)
Free Cash Flow ---------

Weighted Average Cost Of Capital

Share price $ 0.65
Beta 0.000
Diluted Shares Outstanding 22.65
Cost of Debt
Tax Rate 100.00
After-tax Cost of Debt 0.00%
Risk-Free Rate
Market Risk Premium
Cost of Equity 3.759
Total Debt -
Total Equity 14.72
Total Capital -
Debt Weighting -
Equity Weighting -
Wacc

Build Up Free Cash Flow

Year
A/P
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue ---------
Operating Cash Flow ---------
Capital Expenditure ---------
Free Cash Flow ---------
WACC
PV LFCF ---------
SUM PV LFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) -
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -30.33
Equity Value -
Shares Outstanding 22.65
Equity Value Per Share -